{"pmid":32454500,"title":"Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation.","text":["Extracorporeal Blood Purification and Organ Support in the Critically Ill Patient during COVID-19 Pandemic: Expert Review and Recommendation.","Critically ill COVID-19 patients are generally admitted to the ICU for respiratory insufficiency which can evolve into a multiple-organ dysfunction syndrome requiring extracorporeal organ support. Ongoing advances in technology and science and progress in information technology support the development of integrated multi-organ support platforms for personalized treatment according to the changing needs of the patient. Based on pathophysiological derangements observed in COVID-19 patients, a rationale emerges for sequential extracorporeal therapies designed to remove inflammatory mediators and support different organ systems. In the absence of vaccines or direct therapy for COVID-19, extracorporeal therapies could represent an option to prevent organ failure and improve survival. The enormous demand in care for COVID-19 patients requires an immediate response from the scientific community. Thus, a detailed review of the available technology is provided by experts followed by a series of recommendation based on current experience and opinions, while waiting for generation of robust evidence from trials.","Blood Purif","Ronco, Claudio","Bagshaw, Sean M","Bellomo, Rinaldo","Clark, William R","Husain-Syed, Faeq","Kellum, John A","Ricci, Zaccaria","Rimmele, Thomas","Reis, Thiago","Ostermann, Marlies","32454500"],"abstract":["Critically ill COVID-19 patients are generally admitted to the ICU for respiratory insufficiency which can evolve into a multiple-organ dysfunction syndrome requiring extracorporeal organ support. Ongoing advances in technology and science and progress in information technology support the development of integrated multi-organ support platforms for personalized treatment according to the changing needs of the patient. Based on pathophysiological derangements observed in COVID-19 patients, a rationale emerges for sequential extracorporeal therapies designed to remove inflammatory mediators and support different organ systems. In the absence of vaccines or direct therapy for COVID-19, extracorporeal therapies could represent an option to prevent organ failure and improve survival. The enormous demand in care for COVID-19 patients requires an immediate response from the scientific community. Thus, a detailed review of the available technology is provided by experts followed by a series of recommendation based on current experience and opinions, while waiting for generation of robust evidence from trials."],"journal":"Blood Purif","authors":["Ronco, Claudio","Bagshaw, Sean M","Bellomo, Rinaldo","Clark, William R","Husain-Syed, Faeq","Kellum, John A","Ricci, Zaccaria","Rimmele, Thomas","Reis, Thiago","Ostermann, Marlies"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32454500","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1159/000508125","keywords":["continuous renal replacement therapies","cytokine removal","extracorporeal organ support","hemoadsorption","hemoperfusion"],"topics":["Treatment"],"weight":1,"_version_":1667983494595215360,"score":9.490897,"similar":[{"pmid":32035430,"title":"[Recommendations on extracorporeal life support for critically ill patients with novel coronavirus pneumonia].","text":["[Recommendations on extracorporeal life support for critically ill patients with novel coronavirus pneumonia].","Along with the sharp increase of confirmed cases novel coronavirus infection, more critically ill cases require extracorporeal membrane oxygenation (ECMO) support. Based on the clinical data of novel coronavirus pneumonia (NCP), as well as the dada from previous clinical studies and the recommendations from the Extracorporeal Life Support Organization (ELSO), the committee board of the Chinese Society of Extracorporeal Life Support (CSECLS) made this recommendations to guide clinical ECMO application in the patients with NCP.","Zhonghua Jie He He Hu Xi Za Zhi","32035430"],"abstract":["Along with the sharp increase of confirmed cases novel coronavirus infection, more critically ill cases require extracorporeal membrane oxygenation (ECMO) support. Based on the clinical data of novel coronavirus pneumonia (NCP), as well as the dada from previous clinical studies and the recommendations from the Extracorporeal Life Support Organization (ELSO), the committee board of the Chinese Society of Extracorporeal Life Support (CSECLS) made this recommendations to guide clinical ECMO application in the patients with NCP."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","date":"2020-02-10T11:00:00Z","year":2020,"_id":"32035430","source":"PubMed","week":"20207|Feb 10 - Feb 16","doi":"10.3760/cma.j.issn.1001-0939.2020.0009","keywords":["extracorporeal life support","extracorporeal membrane oxygenation","indication","novel coronavirus pneumonia"],"topics":["Treatment"],"weight":1,"_version_":1666138493022109696,"score":201.09776},{"pmid":32324366,"title":"[Organ replacement therapy and life-supporting treatment modalities in critically ill COVID-19 patients].","text":["[Organ replacement therapy and life-supporting treatment modalities in critically ill COVID-19 patients].","In critically ill COVID-19 patients, the failure of the cardiorespiratory system can be due to one of the following: (1) cytokine storm, haemophagocytosis - septic shock, (2) unmanageable hypoxemia, (3) isolated organ failure or as part of multi-organ failure. Herein we give an overview of the therapeutic options for treating or preventing these disease states. In recent years, CytoSorb-haemoperfusion to remove cytokines has shown promising results in the treatment of septic shock. Inhalational nitric oxide (iNO), inhalational epoprostenol and veno-venous extracorporeal membrane oxygenation (ECMO) are options in severe hypoxemia that is unresponsive to conventional mechanical ventilation. Renal failure is a frequent component of the multi-organ failure usually seen with disease progression and necessitates starting one of the available continuous renal replacement modalities. Orv Hetil. 2020; 161(17): 704-709.","Orv Hetil","Berhes, Mariann","Fabian, Akos","Laszlo, Istvan","Vegh, Tamas","Molnar, Csilla","Fulesdi, Bela","Koszta, Gyorgy","32324366"],"abstract":["In critically ill COVID-19 patients, the failure of the cardiorespiratory system can be due to one of the following: (1) cytokine storm, haemophagocytosis - septic shock, (2) unmanageable hypoxemia, (3) isolated organ failure or as part of multi-organ failure. Herein we give an overview of the therapeutic options for treating or preventing these disease states. In recent years, CytoSorb-haemoperfusion to remove cytokines has shown promising results in the treatment of septic shock. Inhalational nitric oxide (iNO), inhalational epoprostenol and veno-venous extracorporeal membrane oxygenation (ECMO) are options in severe hypoxemia that is unresponsive to conventional mechanical ventilation. Renal failure is a frequent component of the multi-organ failure usually seen with disease progression and necessitates starting one of the available continuous renal replacement modalities. Orv Hetil. 2020; 161(17): 704-709."],"journal":"Orv Hetil","authors":["Berhes, Mariann","Fabian, Akos","Laszlo, Istvan","Vegh, Tamas","Molnar, Csilla","Fulesdi, Bela","Koszta, Gyorgy"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32324366","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1556/650.2020.31813","keywords":["covid-19","cytosorb","ecmo","inhalational nitric oxide","inhalalt nitrogen-oxid","intensive therapy","intenziv kezeles"],"locations":["hypoxemia"],"e_drugs":["Epoprostenol","Nitric Oxide"],"topics":["Treatment"],"weight":1,"_version_":1666138493913399296,"score":194.8065},{"pmid":32416769,"title":"Management of acute kidney injury in patients with COVID-19.","text":["Management of acute kidney injury in patients with COVID-19.","The outbreak of coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. Most patients with COVID-19 have mild symptoms, but about 5% develop severe symptoms, which can include acute respiratory distress syndrome, septic shock, and multiple organ failure. Kidney involvement is frequent, with clinical presentation ranging from mild proteinuria to progressive acute kidney injury (AKI) necessitating renal replacement therapy (RRT). An understanding of the pathophysiology and mechanisms of kidney damage and AKI in the setting of critical illness and COVID-19 is emerging, although further research is needed to identify patients at risk of AKI and to guide management strategies. As no specific treatment options exist for AKI secondary to COVID-19, intensive care is largely supportive. Current approaches to prevention and management of AKI, and identification of potential indications for use of RRT and sequential extracorporeal therapies, are based mainly on clinical experience, and AKI strategies are adapted empirically to patients with COVID-19. International collaborative and cross-disciplinary research is needed to obtain adequate evidence to support current clinical approaches and to develop new approaches to management.","Lancet Respir Med","Ronco, Claudio","Reis, Thiago","Husain-Syed, Faeq","32416769"],"abstract":["The outbreak of coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic. Most patients with COVID-19 have mild symptoms, but about 5% develop severe symptoms, which can include acute respiratory distress syndrome, septic shock, and multiple organ failure. Kidney involvement is frequent, with clinical presentation ranging from mild proteinuria to progressive acute kidney injury (AKI) necessitating renal replacement therapy (RRT). An understanding of the pathophysiology and mechanisms of kidney damage and AKI in the setting of critical illness and COVID-19 is emerging, although further research is needed to identify patients at risk of AKI and to guide management strategies. As no specific treatment options exist for AKI secondary to COVID-19, intensive care is largely supportive. Current approaches to prevention and management of AKI, and identification of potential indications for use of RRT and sequential extracorporeal therapies, are based mainly on clinical experience, and AKI strategies are adapted empirically to patients with COVID-19. International collaborative and cross-disciplinary research is needed to obtain adequate evidence to support current clinical approaches and to develop new approaches to management."],"journal":"Lancet Respir Med","authors":["Ronco, Claudio","Reis, Thiago","Husain-Syed, Faeq"],"date":"2020-05-18T11:00:00Z","year":2020,"_id":"32416769","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/S2213-2600(20)30229-0","topics":["Treatment"],"weight":1,"_version_":1667058206819483648,"score":182.92386},{"pmid":32438839,"title":"Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients?","text":["Is there a role for blood purification therapies targeting cytokine storm syndrome in critically severe COVID-19 patients?","The coronavirus disease-19 (COVID-19) has spread over many countries and regions since the end of 2019, becoming the most severe public health event at present. Most of the critical cases developed multiple organ dysfunction, including acute kidney injury (AKI). Cytokine storm syndrome (CSS) may complicate the process of severe COVID-19 patients. This manuscript reviews the different aspects of blood purification in critically ill patients with AKI and increased inflammatory factors, and examines its potential role in severe COVID-19 treatment. Continuous renal replacement therapy (CRRT) has been practiced in many sepsis patients with AKI. Still, the timing and dosing need further robust evidence. In addition to the traditional CRRT, the high-throughput membrane with adsorption function and cytokine adsorption column are two representatives of recently emerging novel membrane technologies. Their potential in removing inflammatory factors and other toxins prospects for the treatment of severe COVID-19.","Ren Fail","Chen, Gang","Zhou, Yangzhong","Ma, Jie","Xia, Peng","Qin, Yan","Li, Xuemei","32438839"],"abstract":["The coronavirus disease-19 (COVID-19) has spread over many countries and regions since the end of 2019, becoming the most severe public health event at present. Most of the critical cases developed multiple organ dysfunction, including acute kidney injury (AKI). Cytokine storm syndrome (CSS) may complicate the process of severe COVID-19 patients. This manuscript reviews the different aspects of blood purification in critically ill patients with AKI and increased inflammatory factors, and examines its potential role in severe COVID-19 treatment. Continuous renal replacement therapy (CRRT) has been practiced in many sepsis patients with AKI. Still, the timing and dosing need further robust evidence. In addition to the traditional CRRT, the high-throughput membrane with adsorption function and cytokine adsorption column are two representatives of recently emerging novel membrane technologies. Their potential in removing inflammatory factors and other toxins prospects for the treatment of severe COVID-19."],"journal":"Ren Fail","authors":["Chen, Gang","Zhou, Yangzhong","Ma, Jie","Xia, Peng","Qin, Yan","Li, Xuemei"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32438839","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1080/0886022X.2020.1764369","keywords":["covid-19","cytosorb","acute kidney injury","blood purification","cytokine storm","oxiris"],"topics":["Treatment"],"weight":1,"_version_":1667535119564406784,"score":180.32169},{"pmid":32464624,"title":"Cytokine Blood Filtration Responses in COVID-19.","text":["Cytokine Blood Filtration Responses in COVID-19.","The real issue with the COVID-19 pandemic is that a rapidly increasing number of patients with life-threatening complications are admitted in hospitals and are not well-administered. Although a limited number of patients use the intensive care unit (ICU), they consume medical resources, safety equipment, and enormous equipment with little possibility of rapid recovery and ICU discharge. This work reviews effective methods of using filtration devices in treatment to reduce the level of various inflammatory mediators and discharge patients from the ICU faster. Extracorporeal technologies have been reviewed as a medical approach to absorb cytokines. Although these devices do not kill or remove the virus, they are a promising solution for treating patients and their faster removal from the ICU, thus relieving the bottleneck.","Blood Purif","Al Shareef, Khaled","Bakouri, Mohsen","32464624"],"abstract":["The real issue with the COVID-19 pandemic is that a rapidly increasing number of patients with life-threatening complications are admitted in hospitals and are not well-administered. Although a limited number of patients use the intensive care unit (ICU), they consume medical resources, safety equipment, and enormous equipment with little possibility of rapid recovery and ICU discharge. This work reviews effective methods of using filtration devices in treatment to reduce the level of various inflammatory mediators and discharge patients from the ICU faster. Extracorporeal technologies have been reviewed as a medical approach to absorb cytokines. Although these devices do not kill or remove the virus, they are a promising solution for treating patients and their faster removal from the ICU, thus relieving the bottleneck."],"journal":"Blood Purif","authors":["Al Shareef, Khaled","Bakouri, Mohsen"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32464624","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1159/000508278","keywords":["blood filtration devices","covid-19","coronavirus","cytokine adsorption","membranes"],"topics":["Treatment"],"weight":1,"_version_":1668079521460387841,"score":175.04808}]}